Veracyte director proposes $375K share sale
Two earlier reported sales by the director were 7,500 shares on September 24 and 5,000 shares on September 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Veracyte, Inc. director Jens Holstein reported a proposed sale of 7,500 common shares, with an aggregate market value of $375,000.00 and an approximate sale date of October 27, 2026. The notice lists 7,500 shares acquired from the issuer through a stock option exercise on October 27, 2026, with cash payment. Holstein’s reported sales during the prior three months were 7,500 shares for $352,500.00 on September 24, 2026, and 5,000 shares for $204,747.00 on September 14, 2026.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Securities To Be Sold financial
Securities Sold During The Past 3 Months financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior VCYT sales did Jens Holstein report?
AI-generated analysis. How Rhea-AI works. Not financial advice.